Table 1.

Epi-drugs approved by the US Food and Drug Administration against cancer and bipolar disorders (27).

Therapeutic compound/drug name	Therapeutic target	Epidrug class/biological effect	Interventional clinical trials status	Number of studies	Same pathologies/disorder investigated
Azacitidine (5-Azacytidine)/Vidaza	DNMT1	DNA Methylation Inhibitor	FDA-approved		Myelodysplastic Syndrome
Decitabine (5-aza-2'-deoxycytidine)/Dacogen	DNMT1	DNA Methylation Inhibitor	FDA-approved		Myelodysplastic Syndrome
Belinostat/Beleodaq	HDACs	Histone Deacetylation Inhibitor	FDA-approved		Relapsed or refractory peripheral T-cell Lymphoma
Romidepsin/Istodax	HDACs	Histone Deacetylation Inhibitor	FDA-approved		Cutaneous T-cell Lymphoma.
Panobinostat (Hydroxamic Acid)/Farydak	HDACs	Histone Deacetylation Inhibitor	FDA-approved		Multiple Myeloma
Valproic acid/depakene and Stavzor	HDACs	Histone Deacetylation Inhibitor	FDA-approved		Bipolar disorder, Adjunctive Therapy in Multiple Seizure

HDACs: Histone deacetylases; DNMT: DNA methyltransferase.